Eurofins Scientific (FR:ERF)
:ERF
Top Page
Eurofins Scientific
(ERF)
Select Model
Select Model
Rating:54Neutral
Price Target:
€62.00
▼(-3.37% Downside)
Action:ReiteratedDate:01/31/26
The score is primarily constrained by financial-quality concerns (higher leverage, weaker free-cash-flow conversion, and margin uncertainty despite strong 2025 revenue growth). Technicals are mixed with near-term softness but an intact longer-term trend, while valuation (P/E ~25 and low yield) offers limited downside support.
Positive Factors
Strong revenue growth
A 36.7% revenue increase in 2025 signals durable demand expansion and higher utilization of Eurofins' lab network. Sustained top-line growth supports scale economics, capacity leverage, and strengthens competitive positioning across regulated testing markets over the medium term.
Negative Factors
Materially higher leverage
Debt-to-equity rising to ~1.53 from ~0.68 meaningfully reduces financial flexibility. Higher leverage increases refinancing and interest-rate risk, constrains capacity for opportunistic investment or buybacks, and magnifies downside if operating cash flow weakens over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue growth
A 36.7% revenue increase in 2025 signals durable demand expansion and higher utilization of Eurofins' lab network. Sustained top-line growth supports scale economics, capacity leverage, and strengthens competitive positioning across regulated testing markets over the medium term.
Read all positive factors
Eurofins Scientific (ERF) vs. iShares MSCI France ETF (EWQ)
Market Cap
€11.29B
Dividend Yield0.97%
Average Volume (3M)260.87K
Price to Earnings (P/E)23.6
Beta (1Y)0.81
Revenue Growth6.25%
EPS Growth18.93%
CountryFR
Employees62,696
SectorGeneral
Sector StrengthN/A
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)1.28
Shares Outstanding176,000,000
10 Day Avg. Volume311,523
30 Day Avg. Volume260,872
Financial Highlights & Ratios
PEG Ratio0.99
Price to Book (P/B)3.17
Price to Sales (P/S)1.54
P/FCF Ratio20.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€77.35Price Target Upside20.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)3.81
Revenue Forecast (FY)€7.67B
Eurofins Scientific Business Overview & Revenue Model
Company Description
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of approximately 200,000 analytical methods to evaluate the safety, identity, composition...
How the Company Makes Money
Eurofins primarily makes money by providing fee-for-service laboratory testing and related analytical services to business and public-sector customers. Revenue is generated when clients submit samples (or outsource ongoing testing programs) and pa...
Eurofins Scientific Financial Statement Overview
Summary
Income Statement
63
Positive
Balance Sheet
46
Neutral
Cash Flow
55
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 7.30B | 6.95B | 6.51B | 6.71B | 6.72B |
| Gross Profit | 793.00M | 4.71B | 620.40M | 4.49B | 4.57B |
| EBITDA | 1.45B | 1.38B | 1.22B | 1.47B | 1.75B |
| Net Income | 475.00M | 406.40M | 310.30M | 610.20M | 782.60M |
Balance Sheet | |||||
| Total Assets | 10.98B | 10.89B | 10.89B | 10.08B | 9.33B |
| Cash, Cash Equivalents and Short-Term Investments | 791.00M | 613.90M | 1.22B | 486.60M | 515.30M |
| Total Debt | 5.43B | 3.61B | 3.93B | 3.33B | 2.75B |
| Total Liabilities | 7.40B | 5.50B | 5.75B | 5.23B | 4.66B |
| Stockholders Equity | 3.54B | 5.34B | 5.08B | 4.78B | 4.65B |
Cash Flow | |||||
| Free Cash Flow | 535.00M | 790.50M | 467.80M | 476.10M | 990.30M |
| Operating Cash Flow | 1.29B | 1.32B | 1.02B | 1.14B | 1.51B |
| Investing Cash Flow | -1.09B | -846.50M | -681.10M | -855.90M | -1.03B |
| Financing Cash Flow | 13.00M | -1.09B | 413.60M | -311.30M | -910.30M |
Eurofins Scientific Technical Analysis
Positive
64.16
Price Trends
64.98
Negative
64.19
Negative
63.58
Positive
Market Momentum
<0.01
Negative
50.92
Neutral
45.52
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ERF, the sentiment is Positive. The current price of 64.16 is above the 20-day moving average (MA) of 62.78, below the 50-day MA of 64.98, and above the 200-day MA of 63.58, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 50.92 is Neutral, neither overbought nor oversold. The STOCH value of 45.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ERF.
Eurofins Scientific Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | €12.07B | 20.60 | 42.80% | 3.32% | 7.12% | 31.41% | |
68 Neutral | €10.65B | 32.73 | 9.69% | 0.82% | 8.28% | -8.08% | |
68 Neutral | €3.02B | 10.97 | 12.62% | 0.41% | 6.97% | -5.59% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | €11.29B | 23.65 | 11.27% | 0.97% | 6.25% | 18.93% | |
52 Neutral | €16.58B | 76.93 | 6.65% | 0.31% | 7.72% | 53.84% |
* General Sector Average
FR:ERF
Eurofins Scientific
64.16
14.97
30.45%
FR:BIM
bioMerieux
90.20
-23.85
-20.91%
FR:BVI
Bureau Veritas
27.21
1.54
5.98%
FR:DIM
Sartorius Stedim Biotech
170.30
0.99
0.58%
FR:VIRP
Virbac SA
360.00
64.88
21.99%
FR:ALBIO
Biosynex SA
0.85
-0.60
-41.66%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.